Flag of the European Union EU Clinical Trials Register Help

Clinical trials for GemOx

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44398   clinical trials with a EudraCT protocol, of which   7410   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    27 result(s) found for: GemOx. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2005-002344-26 Sponsor Protocol Number: R-GEMOX Start Date*: 2005-07-07
    Sponsor Name:GELA
    Full Title: GEMCITABINE-OXALIPLATINE PLUS RITUXIMAB (R-GEMOX) IN REFRACTORY/RELAPSED PATIENTS WITH CD20 POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NON ELIGIBLE FOR HIGH-DOSE CHEMOTHERAPY FOLLOWED BY AUTOTRANSPLAN...
    Medical condition: Refractory/relapsed patients with CD 20 positive large B-cell lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003727-10 Sponsor Protocol Number: MO40598 Start Date*: 2019-12-16
    Sponsor Name: Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F.Hoffmann-La Roche Ltd
    Full Title: A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE SAFETY AND EFFICACY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB PLUS GEMCITABINE PLUS OXALIPLATIN (R-GEMOX) VERSUS R-G...
    Medical condition: Relapsed/refractory diffuse large B-cell lymphoma (DLBL)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10012857 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractory LLT
    21.1 100000004864 10012856 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) recurrent LLT
    21.0 100000004864 10012855 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) IE (Completed) FI (Completed) SE (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-004794-16 Sponsor Protocol Number: 1270.11 Start Date*: 2015-10-21
    Sponsor Name:SCS Boehringer Ingelheim Comm. V
    Full Title: An open label multicenter Phase Ib/II trial to determine the dose of BI 836826 in combination with gemcitabine and oxaliplatin (GemOx) and the efficacy of BI 836826 – GemOx versus rituximab ( R ) w...
    Medical condition: Patients with relapsed/refractory diffuse large B-cell lymphoma including transformed follicular lymphoma) who have been previously treated with an anti-CD20 monoclonal antibody (e.g. rituximab) in...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003735-16 Sponsor Protocol Number: KILT Start Date*: 2021-06-16
    Sponsor Name:LYSARC
    Full Title: A RANDOMIZED NON COMPARATIVE PHASE II STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX ALONE IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA
    Medical condition: Relapsed/refractory PTCL KIR3DL2-positive patients after at least one previous line of systemic based regimen of chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042980 T-cell lymphoma refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042979 T-cell lymphoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-003849-18 Sponsor Protocol Number: CMC-R-GEMOX Start Date*: 2012-06-07
    Sponsor Name:LYSARC
    Full Title: A MULTI-CENTER, PHASE IB/II, OPEN LABEL, SINGLE ARM STUDY OF INOTUZUMAB OZOGAMICIN PLUS RITUXIMAB (R-CMC544) ALTERNATING WITH GEMCITABINE-OXALIPLATIN PLUS RITUXIMAB (R-GEMOX) IN PATIENTS AGED FROM ...
    Medical condition: CD20 and CD22 positive diffuse large B-cell lymphoma in first or second relapse or refractory to first and/or second line treatment
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017428-17 Sponsor Protocol Number: 20091105 Start Date*: 2010-05-31
    Sponsor Name:AZIENDA OSPEDALIERA ORDINE MAURIZIANO
    Full Title: A Phase II Randomized Clinical Trial of Panitumumab plus Gemcitabine and Oxaliplatin (GEMOX) versus GEMOX alone as First Line Treatment in Advanced Biliary Tract Adenocarcinoma
    Medical condition: advanced intrahepatic colangiocarcinoma and extrahepatic biliary adenocarcinoma including gallbladder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008594 LLT
    9.1 10025943 LLT
    9.1 10061239 LLT
    9.1 10022789 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003408-29 Sponsor Protocol Number: 5F9003 Start Date*: 2019-11-04
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma
    Medical condition: Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012821 Diffuse large B-cell lymphoma recurrent PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029624 Non-Hodgkin's lymphoma unspecified histology indolent stage III PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029601 Non-Hodgkin's lymphoma refractory PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029600 Non-Hodgkin's lymphoma recurrent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029623 Non-Hodgkin's lymphoma unspecified histology indolent stage II PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029622 Non-Hodgkin's lymphoma unspecified histology indolent stage I PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065856 Non-Hodgkin's lymphoma unspecified histology indolent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-001021-31 Sponsor Protocol Number: GO41944 Start Date*: 2021-01-22
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF GLOFITAMAB IN COMBINATION WITH GEMCITABINE PLUS OXALIPLATIN VERSUS RITUXIMAB IN COMBINATION WITH GEMCITA...
    Medical condition: Relapsed or refractory diffuse large B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002272-27 Sponsor Protocol Number: DSHNHL2015-1 Start Date*: 2017-04-06
    Sponsor Name:Saarland University
    Full Title: Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to Gemcitabin...
    Medical condition: Patients with first relapse or progression of aggressive Non-Hodgkin’s Lymphoma who are not eligible neither for autologous nor allogeneic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) BE (Completed) NL (Ongoing) PL (Completed) AT (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003313-18 Sponsor Protocol Number: MK-2140-003 Start Date*: 2022-01-10
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Larg...
    Medical condition: Treatment of participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10012857 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-001985-17 Sponsor Protocol Number: H6Q-MC-S013 Start Date*: 2006-10-25
    Sponsor Name:Eli Lilly and Company limited
    Full Title: An Open-label, Single Arm, Phase 2 Study of Rituximab, Gemcitabine, and Oxaliplatin plus Oral Enzastaurin as Treatment for Patients with Relapsed Diffuse Large B-Cell Lymphoma
    Medical condition: high-risk diffuse large B-cell lymphoma (DLBCL )
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012822 Diffuse large B-cell lymphoma refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002654-21 Sponsor Protocol Number: RHMCAN1219 Start Date*: 2017-11-23
    Sponsor Name:University Hospital Southampton NHS Foundation Trust
    Full Title: A PHASE II STUDY OF ATEZOLIZUMAB WITH RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA WHO ARE NOT CANDIDATES FOR HIGH-DOSE THERAPY.
    Medical condition: Diffuse large B-cell lymphoma (most common type of non-Hodgkins lymphoma)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2015-005390-21 Sponsor Protocol Number: IBDCL-GELTAMO-2015 Start Date*: 2016-02-19
    Sponsor Name:GELTAMO
    Full Title: Multicentric phase II trial to evaluate the efficacy and safety of Ibrutinib in combination with rituximab, gemcitabine, oxaliplatin and dexamethasone followed by Ibrutinib maitenance in patients w...
    Medical condition: diffuse large B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-002828-85 Sponsor Protocol Number: RG_15-114 Start Date*: 2017-04-28
    Sponsor Name:University of Birmingham
    Full Title: Paediatric Hepatic International Tumour Trial
    Medical condition: Hepatoblastoma and Hepatocellular Carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062001 Hepatoblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019828 Hepatocellular carcinoma non-resectable LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019830 Hepatocellular carcinoma resectable LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Trial now transitioned) ES (Ongoing) NO (Trial now transitioned) DE (Ongoing) CZ (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) AT (Trial now transitioned) SE (Completed) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007305-36 Sponsor Protocol Number: GEL-TAMO/R-GemOx-08-04/v2 Start Date*: 2009-05-25
    Sponsor Name:GELTAMO (Grupo Español de Linfoma y Transplante Autólogo de Médula Ósea)
    Full Title: Estudio fase II prospectivo, abierto, multicéntrico de Gemcitabina, Oxaliplatino y Dexametasona + Rituximab en pacientes con linfomas agresivos (difuso de céluls grandes B y del manto) en recaída o...
    Medical condition: Linfoma difuso de células grandes B y Linfoma del manto
    Disease: Version SOC Term Classification Code Term Level
    9 10012821 Diffuse large B-cell lymphoma recurrent LLT
    9 10026800 Mantle cell lymphoma recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001560-37 Sponsor Protocol Number: GEM-658-EBE-0024-I Start Date*: Information not available in EudraCT
    Sponsor Name:Medizinische Fakultät der TU-München, vertreten durch den Dekan
    Full Title: Sequentielle Kombination einer Chemotherapie mit Gemcitabine/Oxaliplatin und photodynamischen Therapie beim fortgeschrittenen Gallengangskarzinom
    Medical condition: - advanced cholangiocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008594 Cholangiocarcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004675-11 Sponsor Protocol Number: 133/2004/U Start Date*: 2004-09-14
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Clinical trial of phase II for the a front line treatment of the non-Hodgkin lymphomas of derivation lymphocyte T Gemcitabine and Oxaliplatin GEMOX
    Medical condition: Non Hodgkin s disease of lymphocyte T derivation
    Disease: Version SOC Term Classification Code Term Level
    6.1 10025321 HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003969-33 Sponsor Protocol Number: IPH4102-201 Start Date*: 2019-03-05
    Sponsor Name:Innate Pharma SA
    Full Title: TELLOMAK: T-cell Lymphoma anti-KIR3DL2 therapy. An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in p...
    Medical condition: Advanced T-Cell Lymphomas (TCL), i.e. Cutaneous T Cell Lymphomas (CTCL) and Peripheral T Cell Lympomas (PTCL). CTCL subtypes under investigation: relapsed/refractory Sézary Syndrome (SS), stage IB...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10034622 Peripheral T-cell lymphomas NEC HLT
    20.0 100000004851 10002450 Angioimmunoblastic T-cell lymphomas HLT
    20.0 100000004851 10002235 Anaplastic large cell lymphomas T- and-cell types HLT
    20.0 100000004851 10028484 Mycoses fungoides HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) ES (Temporarily Halted) IT (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003016-27 Sponsor Protocol Number: GCT3013-05 Start Date*: 2021-04-06
    Sponsor Name:Genmab A/S
    Full Title: A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
    Medical condition: B-cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) DK (Trial now transitioned) HU (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) NO (Trial now transitioned) FI (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003908-14 Sponsor Protocol Number: M-2020-371 Start Date*: 2021-07-07
    Sponsor Name:Miltenyi Biomedicine GmbH
    Full Title: A pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diff...
    Medical condition: Relapsed/refractory diffuse large B cell lymphoma (R-R DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003903 B-cell lymphoma refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003902 B-cell lymphoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) LT (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 08 03:22:18 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA